3D Subchondral Bone Shape Biomarkers for OA Responder Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis, such as NSAIDs, corticosteroid injections, hyaluronic acid, microfracture, OATS, ACI, and TKR, fail to demonstrate significant clinical efficacy and safety, and new therapies targeting cartilage degeneration lack regulatory approval due to the discordance between structural and clinical outcomes, while existing structural markers like cartilage thickness do not accurately predict treatment response.
Innovation Solution
Measuring three-dimensional (3D) shape changes in subchondral bones using MRI and active appearance models to identify joints with pathological bone shape changes, and administering a peptide with the amino acid sequence TDLQERGDNDISPFSGDGQPFKD (SEQ ID No: 10) for therapeutic intervention to modify bone structure and improve patient-reported outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If new therapies targeting cartilage degeneration are developed to improve structural outcomes, then cartilage preservation is enhanced, but regulatory approval is denied due to lack of concordance with clinical benefits
Solution Approach 1:
The patent changes the measured parameter from cartilage thickness (structural) to 3D subchondral bone shape (functional correlate). By using active appearance models to quantify bone shape changes, the invention provides a parameter that reflects both structural modification and clinical benefit, thereby bridging the gap between structural outcomes and regulatory requirements for clinical efficacy demonstration
Solution Approach 2:
The patent introduces 3D subchondral bone shape as an intermediary marker between cartilage structure and clinical symptoms. The bone shape changes serve as a mediator that connects structural therapy effects to patient-reported outcomes, providing a bridge that satisfies both structural preservation goals and regulatory clinical benefit requirements
2Device complexity
If existing structural markers like cartilage thickness are used to predict treatment response, then structural measurement is simplified, but prediction accuracy of treatment response is reduced
Solution Approach 1:
The patent transitions from one-dimensional cartilage thickness measurement to three-dimensional subchondral bone shape analysis. By incorporating spatial dimensions and using active appearance models to capture complex bone morphology changes, the invention achieves superior treatment response prediction accuracy while maintaining computational efficiency through automated image analysis algorithms
3Ease of operation
If total knee replacement surgery is performed to achieve immediate pain relief and functional improvement, then patient-reported outcomes are significantly improved, but surgical morbidity and cost increase
Solution Approach 1:
The patent enables preliminary identification of patients who will respond to less invasive therapies by analyzing their baseline 3D subchondral bone shape characteristics. By predicting treatment response before intervention, the invention allows selection of appropriate therapy intensity, potentially avoiding unnecessary major surgeries in patients who will benefit from conservative treatments, thereby reducing surgical morbidity while maintaining effective pain relief for those who need it
Data Source
AI summary
A diagnostic and a method of treatment are disclosed whereby the diagnostic identifies patients more likely to respond to a therapeutic intervention thereby improving clinical benefits including improved joint function, reduced pain, and other clinical symptoms.